Processa Pharmaceuticals (NASDAQ: PCSA), a developer of next-generation chemotherapy drugs that provide a better safety-efficacy profile than widely used FDA-approved counterparts, is hosting a conference call to discuss 2022 year-end results and company updates. The call, which will also be available through a live webcast, is slated to begin at 4:30 p.m. EST on March 30, 2023. Anyone interested in accessing this PCSA-hosted event can dial in or log on 5 to 10 minutes prior to that time. To access the call, dial 888-506-0062 (toll free) or 973-528-0011 (international), then use the entry code 382258. A replay of the call will be available after the event is over. The replay can be accessed by calling 877-481-4010 (toll free) or 919-882-2331 (international), then using the replay code 47882.
To view the webcast, visit https://ibn.fm/Xb3ac
To view the full press release, visit https://ibn.fm/qmAkG
About Processa Pharmaceuticals Inc.
Processa Pharmaceuticals has a mission to develop the next-generation chemotherapies (with existing clinical evidence of safety and efficacy) for cancer patients who need better cancer drugs to extend survival and/or improve their quality of lives. The company uses its Regulatory Science Approach and the principles of the FDA’s Project Optimus Oncology initiative to provide an efficient development program, increase the probability of approval, and provide a safer and better cancer treatment that can be easily differentiated from what is presently on the market and in development. Processa is developing three next-generation chemotherapy oncology treatments: Next-Generation Capecitabine (PCS6422 and Capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic and other cancers), Next-Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast and other cancers), and Next-Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic and other cancers). For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
